Family haploidentical donor-derived cytokine-induced killer cell biotherapy combined with bortezomib in two patients with relapsed multiple myeloma in a non-allogeneic transplant setting

Leukemia and Lymphoma

Volumn 54, Issue 1, 2013, Pages 209-211

  Zhou, Xin ^a   Zhu, Jianping ^b   Sun, Hongli ^a   Shao, Lizheng ^b   Xu, Ming ^b   Guo, Hongfeng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Wuxi Dongfang Cancer Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN LAMBDA CHAIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

AGED; BONE MARROW EXAMINATION; CASE REPORT; CELL THERAPY; CHROMOSOME ANALYSIS; CYTOKINE INDUCED KILLER CELL; DISEASE COURSE; HUMAN; LETTER; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PLASMAPHERESIS; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84870949010     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.701741     Document Type: Letter

References (14)

1. Rajkumar SV. Treatment of multiple myeloma. N at Rev Clin Oncol 2011 ; 8: 479-491.
2. Niu Q, Wang W, Li Y, et al. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol 2011 ; 11: 449-456.
3. Jiang J, Xu N, Wu C, et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res 2006; 26: 2237- 2242. (Pubitemid 43980179)
4. Guo H, Zhou X, Jiang Y, et al. Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: A Chinese experience. Am J Hematol 2010 ; 85: 499-501.
5. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for MM. Leukemia 2006 ; 20: 1467-1473.
6. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLAmatched sibling donors. Transplant 1974; 18: 295- 304.
7. N akamura Y, L eppert M, O'C onnell P, et al. V ariable number of tandem repeat (VNTR) markers for human gene mapping. Science 1987 ; 235: 1616-1622. (Pubitemid 17050143)
8. Introna M, Borleri G, Conti E, et al. Repeated infusions of donorderived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: A phase I study. Haematologica 2007 ; 92: 952-959. (Pubitemid 350144242)
9. Ku ç i S, Rettinger E, Voss B, et al. Effi cient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: Implications for adoptive immunotherapy after allogeneic stem cell transplantation. Haematologica 2010; 95: 1579- 1586.
10. N ishimura R, B aker J, B eilhack A, et al. I n vivo traffi cking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 2008 ; 112: 2563-2574.
11. K ä rre K. Natural killer cell recognition of missing self. Nat Immunol 2008 ; 9: 477-480. (Pubitemid 351560515)
12. van de Donk NW, Kr ö ger N, Hegenbart U, et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 2006 ; 107: 3115-3416.
13. Hoevenaren A, van Vulpen LFD, Levenga H, et al. Bortezomib and donor lymphocyte infusion in multiple myeloma relapsed after allo-SCT does not result in durable remissions. Bone Marrow Transplant 2011 ; 46: 319-321.
14. Kr ö ger N, Shimoni A, Zagrivnaja M, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004 ; 104: 3361-3363. (Pubitemid 39507159)